• UCSBgauchos twitter avatar
    .@UCSB_Baseball is shut out by Sac State in series finale. RECAP: https://t.co/dVAtNSgOFN
    3 hours 52 min ago
  • ucsantabarbara twitter avatar
    We’ve got spirit! How about you? Joining Gaucho Social is an easy and fun way to spread Gaucho pride through your s… https://t.co/y3Hqr8xMEq
    11 hours 7 min ago
  • ArtsandLectures twitter avatar
    RT @brainpicker: So looking forward to my conversation with the wonderful @PicoIyer at the University of Santa Barbara @ArtsandLectures ser…
    1 day 30 min ago
  • UCSBgauchos twitter avatar
    Andrew Martinez (3-5, 4 RBI), Ben Brecht (5 IP, 1 H, 0 K), and Armani Smith (3-5, 3 RBI) team up to take down Sac S… https://t.co/uaCjUxpsEc
    1 day 2 hours ago
  • ucsantabarbara twitter avatar
    Current #UCSB physicist Gary Horowitz got to experience Stephen Hawking’s brilliance firsthand, and recalls Hawking… https://t.co/c19uuFTXbK
    1 day 3 hours ago
  • ucsantabarbara twitter avatar
    The 19th Annual UC LEADS Research and Leadership Symposium brought together undergraduates from across the… https://t.co/1gfuDbw8xd
    1 day 11 hours ago
  • UCSBgauchos twitter avatar
    UCSB MVB became just the second team this year to take a lead on No. 1 and undefeated Long Beach State, but the Gau… https://t.co/faB34xJskD
    1 day 22 hours ago
  • UCSBgauchos twitter avatar
    Women's Tennis: Harvard at UC Santa Barb. (3/16/2018 2:00 PM EDT) Rain Day Leads to Cancellation of UCSB vs Harvard https://t.co/K0rSjkMka2
    1 day 22 hours ago
  • UCSBgauchos twitter avatar
    .@UCSB_Baseball opener vs. Sac St suspended due to rain. Gauchos and Hornets to play two tomorrow. https://t.co/JpJxFxXmbV
    2 days 3 hours ago
  • ucsantabarbara twitter avatar
    Here’s the problem: the bigger the parts in a satellite, the more expensive it is to build, launch, and operate. Lu… https://t.co/KLmIBg84Rb
    2 days 3 hours ago
  • ArtsandLectures twitter avatar
    Considered the world's greatest mezzo-soprano, @JoyceDiDonato entrances audiences across the globe with “a warmth i… https://t.co/L3YuZv7m88
    2 days 4 hours ago
  • brenucsb twitter avatar
    Protecting marine mammals, turtles, and birds by rebuilding global fisheries: #BrenUCSB and @sfgucsb post-docs rele… https://t.co/0HTXyi7Mjg
    2 days 5 hours ago
  • UCSBgauchos twitter avatar
    Logan Hotchkiss and Billy Mullis will represent @UCSBSwimming at the 2018 NCAA Division I Men's Swimming Championsh… https://t.co/e92apKJm4f
    2 days 7 hours ago
  • UCSBLibrary twitter avatar
    #deadweek means you'll have to wait just a bit longer to celebrate #worldsleepday. You're almost there, Gauchos!
    2 days 8 hours ago

Delivering Drugs to the Right Place

Thomas Weimbs has developed a targeted drug delivery method that could potentially slow the progression of polycystic kidney disease
Thursday, June 25, 2015 - 09:30
Santa Barbara, CA

Thomas Weimbs.jpg

Thomas Weimbs

Thomas Weimbs

Photo Credit: 

Sonia Fernandez

For the 12 million people worldwide who suffer from polycystic kidney disease (PKD), an inherited disorder with no known cure, a new treatment option may be on the horizon.

PKD is a condition in which clusters of benign cysts develop within the kidneys. They vary in size, and as they accumulate more and more fluid, they can become very large. Among the common complications of PKD are high blood pressure and kidney failure.

Now, Thomas Weimbs, a professor in UC Santa Barbara’s Department of Molecular, Cellular, and Developmental Biology, has developed a novel strategy for targeting therapeutic antibodies to polycystic kidneys. He notes that the strategy opens up the possibility of repurposing a large number of existing drugs for PKD therapy.

Therapeutic antibodies — a class of biologics — are already being used extensively to treat a variety of diseases from cancer to autoimmune disorders. These biologic therapies use an antibody class called immunoglobulin-G (IgG) to bind to and prevent the activity of specific proteins or growth factors. However, in PKD, the growth factors shown to promote cyst growth reside in fluid trapped in the interior space of a cyst, called a lumen, to which IgG antibodies have no access.

Weimbs and his team have found a method that enables another class of antibodies, immunoglobulin-A (IgA), to penetrate the cyst wall. The researchers’ results appear in the Journal of Biological Chemistry.

Weimbs, who has been working on PKD for more than a decade, had an aha moment when he remembered his previous research as postdoctoral scholar at UC San Francisco. This research dealt with the question of how IgA could cross a cell layer by binding to polymeric immunoglobulin receptors (pIgR). Earlier work Weimbs conducted at UCSB had shown that the transcription factor called STAT6 is overly active in PKD, and he also recalled that STAT6 had been shown to drive the expression of pIgR in other organs.

“I put one and one together,” Weimbs said. “I thought if STAT6 is highly active in polycystic kidneys, maybe it also expresses a lot of pIgR — and that turned out to be the case. So we tested this in mouse models and in human polycystic kidney tissues, and, in both cases, high levels of pIgR were expressed in kidney cysts.”

Weimbs and his team found that when they injected IgA into mice, about 7 percent of the injected IgA remained inside the cyst lumens of polycystic kidneys. “This suggests that the IgA gets taken up and is trapped inside because these cysts don’t have an exit,” Weimbs said. “So we end up with a way of exploiting the pIgR system for targeting these antibodies specifically to the polycystic kidney.”

The key is using molecular cloning to reformat an existing IgG antibody to IgA. Then the pIgR system carries the IgA antibody inside the cyst, where it neutralizes a specific receptor.

“Our strategy allows for the repurposing of thousands of existing monoclonal antibodies that have already been developed, which opens up a whole new class of therapeutics not previously used for PKD therapy,” Weimbs concluded. “This paper is proof of concept that we can use IgA to target polycystic kidneys. The next hurdle will be proof of therapeutic efficacy where we actually take an IgA antibody targeted to a specific protein or growth factor and see if it can inhibit cyst growth.”

Contact Info: 

Julie Cohen
(805) 893-7220